Castle Biosciences CSTL Business Segments — Total stock-based compensation expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Castle Biosciences in its filing.
Tagged under the XBRL concept us-gaap:AllocatedShareBasedCompensationExpense.
The official record: Castle Biosciences’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Castle Biosciences's business segments — total stock-based compensation expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Castle Biosciences's business segments — total stock-based compensation expense?
- Castle Biosciences (CSTL) reported business segments — total stock-based compensation expense of $9.78M in Q1 2026.
- How has Castle Biosciences's business segments — total stock-based compensation expense changed year-over-year?
- Castle Biosciences's business segments — total stock-based compensation expense decreased by 12.6% year-over-year, from $11.18M to $9.78M.
- What is the long-term trend for Castle Biosciences's business segments — total stock-based compensation expense?
- Over 3 years (2022 to 2025), Castle Biosciences's business segments — total stock-based compensation expense has grown at a 8.1% compound annual growth rate (CAGR), from $36.32M to $45.89M.
- What does business segments — total stock-based compensation expense mean?
- This represents the total non-cash expense recognized for equity-based awards granted to employees and personnel within the reportable segment. It serves as a measure of the cost of human capital retention and alignment through equity incentives.